benzofurans and 6-(2-aminopropyl)benzofuran

This study aimed to review the available evidence-based literature on novel psychoactive substances and to inform health care professionals.. Internet searches were carried out using Google and Yahoo by using specific key words. For each set of key words, the first 100 websites identified by Google and Yahoo were fully assessed, together with a further 5% of random samples selected by research randomizer of the remaining websites. Thus, a list of unique web forums was identified, and qualitative information was extracted. Available evidence-based literature were reviewed along with a user's experimentation with mephedrone, NRG-1, NRG-2 and Benzofury.. It showed that when a substance (mephedrone) became controlled, the vendors aggressively promote the sale of other new compounds (NRG-1, NRG-2, Benzofury) to attract vulnerable adults. The characteristics, toxicity and suggested management of these new compounds (NRG-1, NRG-2, Benzofury) are discussed.. The arrival of hundreds of novel psychoactive substances for sale online has raised a number of public health and legal issues. Although evidence-based literature remains limited, few studies identified that most products do not contain the ingredients as advertised. Better levels of international cooperation and rapid share of available information may be needed to tackle this emerging problem.

Topics: Animals; Benzofurans; Humans; Illicit Drugs; Male; Middle Aged; Paranoid Disorders; Pentanones; Propylamines; Pyrrolidines; Random Allocation; Tachycardia

New phenylethylamine derivatives are among the most commonly abused new psychoactive substances. They are synthesized and marketed in lieu of classical amphetaminic stimulants, with no previous safety testing. Our study aimed to determine the in vitro hepatotoxicity of two benzofurans [6-(2-aminopropyl)benzofuran (6-APB) and 5-(2-aminopropyl)benzofuran (5-APB)] that have been misused as 'legal highs'. Cellular viability was assessed through the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay, following 24-h drug exposure of human hepatoma HepaRG cells (EC

Topics: Animals; Autophagy; Benzofurans; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Designer Drugs; Hep G2 Cells; Hepatocytes; Humans; Isomerism; Male; Membrane Potential, Mitochondrial; Oxidative Stress; Propylamines; Rats, Wistar; Reactive Oxygen Species

The nonmedical use of new psychoactive substances (NPS) is a worldwide public health concern. The so-called "benzofury" compounds, 5-(2-aminopropyl)benzofuran (5-APB) and 6-(2-aminopropyl)benzofuran (6-APB), are NPS with stimulant-like properties in human users. These substances are known to interact with monoamine transporters and 5-HT receptors in transfected cells, but less is known about their effects in animal models.. Here, we used in vitro monoamine transporter assays in rat brain synaptosomes to characterize the effects of 5-APB and 6-APB, together with their N-methyl derivatives 5-MAPB and 6-MAPB, in comparison with 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA). In vivo neurochemical and behavioral effects of 5-APB (0.3 and 1.0 mg/kg, i.v.) and 6-APB (0.3 and 1.0 mg/kg, i.v.) were assessed in comparison with MDA (1.0 and 3.0 mg/kg, i.v.) using microdialysis sampling in the nucleus accumbens of conscious male rats.. All four benzofuran derivatives were substrate-type releasers at dopamine transporters (DAT), norepinephrine transporters (NET), and serotonin transporters (SERT) with nanomolar potencies, similar to the profile of effects produced by MDA and MDMA. However, the benzofurans were at least threefold more potent than MDA and MDMA at evoking transporter-mediated release. Like MDA, both benzofurans induced dose-related elevations in extracellular dopamine and serotonin in the brain, but benzofurans were more potent than MDA. The benzofuran derivatives also induced profound behavioral activation characterized by forward locomotion which lasted for at least 2 h post-injection.. Overall, benzofurans are more potent than MDA in vitro and in vivo, producing sustained stimulant-like effects in rats. These data suggest that benzofuran-type compounds may have abuse liability and could pose risks for adverse effects, especially if used in conjunction with abused drugs or medications which enhance monoamine transmission in the brain.

Topics: 3,4-Methylenedioxyamphetamine; Animals; Benzofurans; Dopamine Plasma Membrane Transport Proteins; Male; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; Psychotropic Drugs; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins

The number of so-called new psychoactive substances (NPS) is still increasing by modification of the chemical structure of known (scheduled) drugs. As analogues of amphetamines, 2-aminopropyl-benzofurans were sold. They were consumed because of their euphoric and empathogenic effects. After the 5-(2-aminopropyl)benzofurans, the 6-(2-aminopropyl)benzofuran isomers appeared. Thus, the question arose whether the metabolic fate, the mass spectral fragmentation, and the detectability in urine are comparable or different and how an intake can be differentiated. In the present study, 6-(2-aminopropyl)benzofuran (6-APB) and its N-methyl derivative 6-MAPB (N-methyl-6-(2-aminopropyl)benzofuran) were investigated to answer these questions. The metabolites of both drugs were identified in rat urine and human liver preparations using GC-MS and/or liquid chromatography-high resolution-mass spectrometry (LC-HR-MS(n)). Besides the parent drug, the main metabolite of 6-APB was 4-carboxymethyl-3-hydroxy amphetamine and the main metabolites of 6-MAPB were 6-APB (N-demethyl metabolite) and 4-carboxymethyl-3-hydroxy methamphetamine. The cytochrome P450 (CYP) isoenzymes involved in the 6-MAPB N-demethylation were CYP1A2, CYP2D6, and CYP3A4. An intake of a common users' dose of 6-APB or 6-MAPB could be confirmed in rat urine using the authors' GC-MS and the LC-MS(n) standard urine screening approaches with the corresponding parent drugs as major target allowing their differentiation. Furthermore, a differentiation of 6-APB and 6-MAPB in urine from their positional isomers 5-APB and 5-MAPB was successfully performed after solid phase extraction and heptafluorobutyrylation by GC-MS via their retention times.

Topics: Animals; Benzofurans; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Designer Drugs; Gas Chromatography-Mass Spectrometry; Humans; Inactivation, Metabolic; Isomerism; Male; Mass Spectrometry; Microsomes, Liver; Propylamines; Rats, Wistar; Solid Phase Extraction

Phenethylamine-based designer drugs are prevalent within the new psychoactive substance market. Characterisation of their metabolites is important in order to identify suitable biomarkers which can be used for better monitoring their consumption. Careful design of in vitro metabolism experiments using subcellular liver fractions will assist in obtaining reliable outcomes for such purposes. The objective of this study was to stepwise investigate the in vitro human metabolism of seven phenethylamine-based designer drugs using individual families of enzymes. This included para-methoxyamphetamine, para-methoxymethamphetamine, 4-methylthioamphetamine, N-methyl-benzodioxolylbutanamine, benzodioxolylbutanamine, 5-(2-aminopropyl) benzofuran and 6-(2-aminopropyl) benzofuran. Identification and structural elucidation of the metabolites was performed using liquid chromatography-quadrupole-time-of-flight mass spectrometry. The targeted drugs were mainly metabolised by cytochrome P450 enzymes via O-dealkylation as the major pathway, followed by N-dealkylation, oxidation of unsubstituted C atoms and deamination (to a small extent). These drugs were largely free from Phase II metabolism. Only a limited number of metabolites were found which was consistent with the existing literature for other phenethylamine-based drugs. Also, the metabolism of most of the targeted drugs progressed at slow rate. The reproducibility of the identified metabolites was assessed through examining formation patterns using different incubation times, substrate and enzyme concentrations. Completion of the work has led to a set of metabolites which are representative for specific detection of these drugs in intoxicated individuals and also for meaningful evaluation of their use in communities by wastewater-based drug epidemiology.

Topics: 3,4-Methylenedioxyamphetamine; Amines; Amphetamines; Benzodioxoles; Benzofurans; Butylamines; Catalysis; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Cytosol; Designer Drugs; Dose-Response Relationship, Drug; Female; Humans; Likelihood Functions; Liver; Male; Mass Spectrometry; Methamphetamine; Microsomes, Liver; Models, Chemical; Phenethylamines; Propylamines; Reproducibility of Results; Substance Abuse Detection; Wastewater; Water Purification

5-APB, commonly marketed as 'benzofury' is a new psychoactive substance and erstwhile 'legal high' which has been implicated in 10 recent drug-related deaths in the UK. This drug was available on the internet and in 'head shops' and was one of the most commonly sold legal highs up until its recent UK temporary ban (UK Home Office). Despite its prominence, very little is known about its pharmacology. This study was undertaken to examine the pharmacology of 5-APB in vitro. We hypothesised that 5-APB would activate the dopamine and 5-HT systems which may underlie its putative stimulant and hallucinogenic effects. Autoradiographic studies showed that 5-APB displaced both [(125)I] RTI-121 and [(3)H] ketanserin from rat brain tissue suggesting affinity at the dopamine transporter and 5-HT2 receptor sites respectively. Voltammetric studies in rat accumbens brain slices revealed that 5-APB slowed dopamine reuptake, and at high concentrations caused reverse transport of dopamine. 5-APB also caused vasoconstriction of rat aorta, an effect antagonised by the 5-HT2A receptor antagonist ketanserin, and caused contraction of rat stomach fundus, which was reversed by the 5-HT2B receptor antagonist RS-127445. These data show that 5-APB interacts with the dopamine transporter and is an agonist at the 5-HT2A and 5-HT2B receptors in the rat. Thus 5-APB's pharmacology is consistent with it having both stimulant and hallucinogenic properties. In addition, 5-APB's activity at the 5-HT2B receptor may cause cardiotoxicity.

Topics: Animals; Aorta; Benzofurans; Brain; Cocaine; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; In Vitro Techniques; Iodine Isotopes; Ketanserin; Male; Muscle Contraction; N-Methyl-3,4-methylenedioxyamphetamine; Propylamines; Protein Binding; Rats; Rats, Wistar; Receptors, Serotonin, 5-HT2; Serotonin Agents; Tritium; Vasoconstriction

The illicit drug market of psychoactive substances for human abuse is continuously expanding and developing. Besides already known substance classes like cathinones, amphetamines or synthetic cannabinoids, further derivatives such as benzofurys, thiophenes, and structural analogues of methylphenidate entered the global market recently. As many of these new compounds contain a stereogenic centre it is supposed that their isomers may differ in their pharmacological effects as it is the case with amphetamines or several chiral active pharmaceutical ingredients, for instance. In the course of this study, a method for the chiral separation of a set of 16 recreational drugs by CE was developed. The aim was to separate the analytes into their enantiomers at equal conditions within short time. Sulfobutylether β-cyclodextrin served as chiral selector in an aqueous ammonium acetate solution containing ACN. For method optimization, methedrone and ethylphenidate were used as model compounds to find the appropriate concentration of chiral selector. Moreover, the influence of the pH value on enantioseparation was tested. Fourteen or 16 mM sulfobutylether β-cyclodextrin, 50 mM ammonium acetate solution (pH 4.5) with 10% ACN were found to be optimal for enantioseparation of seven benzofurys, four cathinones, two diphenidines, ethylphenidate, methiopropamine, and thiothinone. Most of them were baseline resolved at migration times below 25 min.

Topics: Acetonitriles; Benzofurans; beta-Cyclodextrins; Electrophoresis, Capillary; Hydrogen-Ion Concentration; Illicit Drugs; Methylphenidate; Propylamines; Psychotropic Drugs; Reproducibility of Results; Stereoisomerism; Substance Abuse Detection

There is evidence from around Europe of the availability and use of 6-(2-aminopropyl)benzofuran (6-APB) as a recreational drug. However, there is currently limited information on the acute toxicity of this compound. We describe here a case of acute toxicity associated with recreational use of legal high (6-APB) and cannabis, in which the comprehensive toxicological analysis confirmed the presence of a significant amount of 6-APB together with metabolites of both tetrahydrocannabinol and the synthetic cannabinoid receptor agonist (JWH-122).. A 21-year-old gentleman with no previous medical and psychiatric history was brought to the emergency department (ED) after he had developed agitation and paranoid behaviour following the use of 6-APB purchased over the Internet. There was no obvious medical cause for his acute psychosis. He required diazepam to control his agitation and was subsequently transferred to a psychiatric hospital for ongoing management of his psychosis. Toxicological screening of a urine sample collected after presentation to the ED detected 6-APB, with an estimated urinary concentration of 2,000 ng/ml; other drugs were also detected, but at lower concentrations including metabolites of the synthetic cannabinoid receptor agonist JWH-122 and tetrahydrocannabinol.. This is the first case of analytically confirmed acute toxicity associated with the detection of 6-APB which will provide some information on acute toxicity of this drug to help clinicians with the management of such patients and legislative authorities in their consideration for the need of its control.

Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Benzofurans; Cannabinoids; Dronabinol; Emergency Medical Services; Humans; Illicit Drugs; Indoles; Internet; Male; Marijuana Abuse; Marijuana Smoking; Naphthalenes; Paranoid Behavior; Propylamines; Psychoses, Substance-Induced; Psychotropic Drugs; Self-Injurious Behavior; Severity of Illness Index; Substance Abuse Detection; Young Adult